• 
• 
• 

FDA News and Drug Updates

FDA Approves 2 New Biosimilars for Patients with Cancer

FDA News - September 2018

A Dynamic FDA Has Led to More Rapid Cancer Drug Development

Welcome to the Third Annual Oncology Guide to New FDA Approvals

Adverse Effects

Understanding Immunotherapy Late Adverse Effects in Cancer Survivors

Meg Barbor, MPH

Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer

Adverse Events Associated with Checkpoint Inhibitors

Alice Goodman

View All Supportive Care Articles

Immunotherapy

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Immune Checkpoint Inhibitors: Test Your Knowledge Level

Eileen Koutnik-Fotopoulos

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

Wayne Kuznar

View All Breast Cancer Articles

Conference Correspondent

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia

“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference

Silent Patients Find Their Voices Through an Advocate’s Journey

View All Conference Correspondent Articles

Most Popular Articles

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

TOP Web Exclusives - Immunotherapy, Multiple Myeloma

FDA Approves 2 New Biosimilars for Patients with Cancer

TOP Web Exclusives - FDA Approvals, News & Updates

Breaking News from the 2018 Meeting of the European Society for Medical Oncology (ESMO)

Conference Correspondent  - ESMO 2018 Wrap Up

Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma

Wayne Kuznar

TOP Web Exclusives - Multiple Myeloma

LOXO-292 Highly Effective in RET-Positive Cancers

TOP Web Exclusives - Emerging Therapies